Extending killer Ig-like receptor function: From HLA class I recognition to sensors of microbial products

Trends in Immunology

Volumn 31, Issue 8, 2010, Pages 289-294

  Sivori, Simona ^a   Falco, Michela ^b   Moretta, Lorenzo ^a,b   Moretta, Alessandro ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b G GASLINI INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; CYTOKINE; HLA ANTIGEN CLASS 1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DL2; TOLL LIKE RECEPTOR;

ANTIGEN BINDING; ARTICLE; CYTOKINE RELEASE; DRUG RECEPTOR BINDING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA; LYMPHOCYTOTOXICITY; NATURAL KILLER CELL; NONHUMAN; PROTEIN ANALYSIS; PROTEIN FUNCTION; RECEPTOR BINDING; CPG ISLAND; IMMUNOLOGY;

CPG ISLANDS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; KILLER CELLS, NATURAL; RECEPTORS, KIR;

EID: 77955280347     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2010.05.007     Document Type: Article

References (85)

1. Moretta A. Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat. Rev. Immunol. 2002, 2:957-964.
2. Caligiuri M.A. Human natural killer cells. Blood 2008, 112:461-469.
3. Vivier E., et al. Functions of natural killer cells. Nat. Immunol. 2008, 9:503-510.
4. Moretta A., et al. p58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities. J. Exp. Med. 1993, 178:597-604.
5. Wagtmann N., et al. Molecular clones of the p58 NK cell receptor reveal immunoglobulin-related molecules with diversity in both the extra- and intracellular domains. Immunity 1995, 2:439-449.
6. Colonna M., Samaridis J. Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells. Science 1995, 268:405-408.
7. Moretta A., et al. Receptors for HLA class-I molecules in human natural killer cells. Annu. Rev. Immunol. 1996, 14:619-648.
8. Lanier L.L., et al. NK cell receptors. Annu. Rev. Immunol. 1998, 16:359-393.
9. Moretta L., et al. Killer immunoglobulin-like receptors. Curr. Opin. Immunol. 2004, 16:626-633.
10. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat. Rev. Immunol. 2005, 5:201-214.
11. Braud V.M., et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998, 391:795-799.
12. Moretta A., et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu. Rev. Immunol. 2001, 19:197-223.
13. Sivori S., et al. p46, a novel natural killer cell-specific surface molecule that mediates cell activation. J. Exp. Med. 1997, 186:1129-1136.
14. Walzer T., et al. Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:3384-3389.
15. Raulet D.H. Roles of the NKG2D immunoreceptor and its ligands. Nat. Rev. Immunol. 2003, 3:781-790.
16. Bottino C., et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J. Exp. Med. 2003, 198:557-567.
17. Bottino C., et al. Cellular ligands of activating NK receptors. Trends Immunol. 2005, 26:221-226.
18. Marcenaro E., et al. Human NK cells directly recognize Mycobacterium bovis via TLR2 and acquire the ability to kill monocyte-derived DC. Int. Immunol. 2008, 20:1155-1167.
19. Agaugué S., et al. Human natural killer cells exposed to IL-2, IL-12, IL-18, or IL-4 differently modulate priming of naive T cells by monocyte-derived dendritic cells. Blood 2008, 112:1776-1783.
20. Sivori S., et al. CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:10116-10121.
21. Bennett M. Biology and genetics of hybrid resistance. Adv. Immunol. 1987, 41:333-445.
22. Biassoni R., et al. Amino acid substitutions can influence the natural killer (NK)-mediated recognition of HLA-C molecules. Role of serine-77 and lysine-80 in the target cell protection from lysis mediated by " group 2" or " group 1" NK clones. J. Exp. Med. 1995, 182:605-609.
23. Winter C.C., Long E.O. A single amino acid in the p58 killer cell inhibitory receptor controls the ability of natural killer cells to discriminate between the two groups of HLA-C allotypes. J. Immunol. 1997, 158:4026-4028.
24. Moretta A., et al. Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells. J. Exp. Med. 1995, 182:875-884.
25. Biassoni R., et al. The human leukocyte antigen (HLA)-C-specific " activatory" or " inhibitory" natural killer cell receptors display highly homologous extracellular domains but differ in their transmembrane and intracytoplasmic portions. J. Exp. Med. 1996, 183:645-650.
26. Biassoni R., et al. Role of amino acid position 70 in the binding affinity of p50.1 and p58.1 receptors for HLA-Cw4 molecules. Eur. J. Immunol. 1997, 27:3095-3099.
27. Chewning J.H., et al. KIR2DS1-positive NK cells mediate alloresponse against the C2 HLA-KIR ligand group in vitro. J. Immunol. 2007, 179:854-868.
28. Stewart C.A., et al. Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:13224-13229.
29. Graef T., et al. KIR2DS4 is a product of gene conversion with KIR3DL2 that introduced specificity for HLA-A*11 while diminishing avidity for HLA-C. J. Exp. Med. 2009, 206:2557-2572.
30. Vilches C., Parham P. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu. Rev. Immunol. 2002, 20:217-251.
31. Bottino C., et al. A novel surface molecule homologous to the p58/p50 family of receptors is selectively expressed on a subset of human natural killer cells and induces both triggering of cell functions and proliferation. Eur. J. Immunol. 1996, 26:1816-1824.
32. Della Chiesa M., et al. Evidence that the KIR2DS5 gene codes for a surface receptor triggering natural killer cell function. Eur. J. Immunol. 2008, 38:2284-2289.
33. Kikuchi-Maki A., et al. KIR2DL4 is an IL-2-regulated NK cell receptor that exhibits limited expression in humans but triggers strong IFN-gamma production. J. Immunol. 2003, 171:3415-3425.
34. Estefanía E., et al. Human KIR2DL5 is an inhibitory receptor expressed on the surface of NK and T lymphocyte subsets. J. Immunol. 2007, 178:4402-4410.
35. D'Andrea A., et al. Molecular cloning of NKB1. A natural killer cell receptor for HLA-B allotypes. J. Immunol. 1995, 155:2306-2310.
36. Gumperz J.E., et al. The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J. Exp. Med. 1995, 181:1133-1144.
37. Pende D., et al. The natural killer cell receptor specific for HLA-A allotypes: a novel member of the p58/p70 family of inhibitory receptors that is characterized by three immunoglobulin-like domains and is expressed as a 140-kD disulphide-linked dimer. J. Exp. Med. 1996, 184:505-518.
38. Döhring C., et al. A human killer inhibitory receptor specific for HLA-A3. J. Immunol. 1996, 156:3098-3101.
39. Moretta A., et al. Identification of four subsets of human CD3-CD16+ natural killer (NK) cells by the expression of clonally distributed functional surface molecules: correlation between subset assignment of NK clones and ability to mediate specific alloantigen recognition. J. Exp. Med. 1990, 172:1589-1598.
40. Uhrberg M., et al. Human diversity in killer cell inhibitory receptor genes. Immunity 1997, 7:753-763.
41. Valiante N.M., et al. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity 1997, 7:739-751.
42. Ljunggren H.G., Kärre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol. Today 1990, 11:237-244.
43. Anfossi N., et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity 2006, 25:331-342.
44. Fauriat C., et al. Education of human natural killer cells by activating killer cell immunoglobulin-like receptors. Blood 2010, 115:1166-1174.
45. Orr M.T., et al. " Unlicensed" natural killer cells dominate the response to cytomegalovirus infection. Nat. Immunol. 2010, 11:321-328.
46. Ciccone E., et al. Involvement of HLA class I alleles in natural killer (NK) cell-specific functions: expression of HLA-Cw3 confers selective protection from lysis by alloreactive NK clones displaying a defined specificity (specificity 2). J. Exp. Med. 1992, 176:963-971.
47. Ruggeri L., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
48. Velardi A., et al. NK cells: a lesson from mismatched hematopoietic transplantation. Trends Immunol. 2002, 23:438-444.
49. Pende D., et al. Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood 2005, 105:2066-2073.
50. Moretta A., et al. Human NK cells: from HLA class I-specific killer Ig-like receptors to the therapy of acute leukemias. Immunol. Rev. 2008, 224:58-69.
51. Pende D., et al. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood 2009, 113:3119-3129.
52. Moretta L., et al. Natural killer alloeffector responses in haploidentical hemopoietic stem cell transplantation to treat high-risk leukemias. Tissue Antigens 2010, 75:103-109.
53. Parham P., McQueen K.L. Alloreactive killer cells: hindrance and help for haematopoietic transplants. Nat. Rev. Immunol. 2003, 3:108-122.
54. Ruggeri L., et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007, 110:433-440.
55. Farag S.S., et al. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 2002, 100:1935-1947.
56. Miller J.S., et al. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood 2007, 109:5058-5061.
57. Marcenaro E., et al. Uptake of CCR7 and acquisition of migratory properties by human KIR+ NK cells interacting with monocyte-derived DC or EBV cell lines: regulation by KIR/HLA-class I interaction. Blood 2009, 114:4108-4116.
58. Fernandes N.C., et al. A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood 2005, 105:4416-4423.
59. Kim S., et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005, 436:709-713.
60. Martelli M.F., Reisner Y. Haploidentical 'megadose' CD34+ cell transplants for patients with acute leukemia. Leukemia 2002, 16:404-405.
61. Muzio M., et al. Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J. Immunol. 2000, 164:5998-6004.
62. Chalifour A., et al. Direct bacterial protein PAMP recognition by human NK cells involves TLRs and triggers alpha-defensin production. Blood 2004, 104:1778-1783.
63. Hart O.M., et al. TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production. J. Immunol. 2005, 175:1636-1642.
64. Sivori S., et al. Heterogeneity of TLR3 mRNA transcripts and responsiveness to poly (I:C) in human NK cells derived from different donors. Int. Immunol. 2007, 19:1341-1348.
65. Sivori S., et al. Comparison of different CpG oligodeoxynucleotide classes for their capability to stimulate human NK cells. Eur. J. Immunol. 2006, 36:961-967.
66. Latz E., et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat. Immunol. 2004, 5:190-198.
67. Leifer C.A., et al. TLR9 is localized in the endoplasmic reticulum prior to stimulation. J. Immunol. 2004, 173:1179-1183.
68. Sivori, S. et al. (2010) A novel KIR-associated function: evidence that CpG DNA uptake and shuttling to early endosomes is mediated by KIR3DL2. Blood. [Epub ahead of print].
69. Bagot M., et al. CD4(+) cutaneous T cell lymphoma cells express the p140-killer cell immunoglobulin-like receptor. Blood 2001, 97:1388-1391.
70. Wechsler J., et al. Killer cell immunoglobulin-like receptor expression delineates in situ Sezary syndrome lymphocytes. J. Pathol. 2003, 199:77-83.
71. Jackow C.M., et al. Association of erythrodermic cutaneous T cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T cell receptor V beta gene expansion. Blood 1997, 89:32-40.
72. Chang Y.T., et al. Detection of Epstein-Barr virus and HTLV-I in T cell lymphomas of skin in Taiwan. Am. J. Dermatopathol. 1998, 20:250-254.
73. Abrams J.T., et al. Association between Sézary T cell-activating factor, Chlamydia pneumoniae, and cutaneous T cell lymphoma. Ann. N. Y. Acad. Sci. 2001, 941:69-85.
74. Herne K.L., et al. Cytomegalovirus seropositivity is significantly associated with mycosis fungoides and Sézary syndrome. Blood 2003, 101:2132-2136.
75. Khakoo S.I., et al. The D0 domain of KIR3D acts as a major histocompatibility complex class I binding enhancer. J. Exp. Med. 2002, 196:911-921.
76. Rajalingam R., et al. Domain shuffling has been the main mechanism forming new hominoid killer cell Ig-like receptors. J. Immunol. 2004, 172:356-369.
77. Wilson M.J., et al. Plasticity in the organization and sequences of human KIR/ILT gene families. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:4778-4783.
78. Willemze R., et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005, 105:3768-3785.
79. Poszepczynska-Guigné E., et al. CD158k/KIR3DL2 is a new phenotypic marker of Sezary cells: relevance for the diagnosis and follow-up of Sezary syndrome. J. Invest. Dermatol. 2004, 122:820-823.
80. Bouaziz J.D., et al. Absolute CD3+ CD158k+ lymphocyte count is reliable and more sensitive than cytomorphology to evaluate blood tumour burden in Sezary syndrome. Br. J. Dermatol. 2010, 162:123-128.
81. Mingari M.C., et al. Cytolytic T lymphocytes displaying natural killer (NK)-like activity: expression of NK-related functional receptors for HLA class I molecules (p58 and CD94) and inhibitory effect on the TCR-mediated target cell lysis or lymphokine production. Int. Immunol. 1995, 7:697-703.
82. Mingari M.C., et al. Regulation of KIR expression in human T cells: a safety mechanism that may impair protective T cell responses. Immunol. Today 1998, 19:153-157.
83. Moretta L., et al. NK-CTLs, a novel HLA-E-restricted T cell subset. Trends Immunol. 2003, 24:136-143.
84. Vivier E., Anfossi N. Inhibitory NK cell receptors on T cells: witness of the past, actors of the future. Nat. Rev. Immunol. 2004, 4:190-198.
85. Moesta A.K., et al. Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3. J. Immunol. 2008, 180:3969-3979.